Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer's disease ... including amyloid beta, tau, ...

A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...

And also we found the significant effects in terms of ADAS-Cog [Alzheimer's Disease Assessment Scale-Cognitive Subscale], ...

Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...

Prothena is evaluating PRX012 — a wholly owned investigational next-generation subcutaneous, single-injection once-monthly antibody delivered subcutaneously targeting a key epitope at the N-terminus ...

Acumen Pharmaceuticals, Inc. ( (ABOS) ) has released its Q3 earnings. Here is a breakdown of the information Acumen Pharmaceuticals, Inc.

This focus could potentially offer a more effective and safer treatment for Alzheimer’s, addressing a critical need ... is a subclass monoclonal antibody which selectively targets amyloid-beta ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

and they work by taking out amyloid beta from the brain. Amyloid is part of what causes Alzheimer's disease. Now, what we're ...

New research offers hope for delaying Alzheimer’s disease progression by years after initial diagnosis. Alzheimer’s disease is a leading cause of death among those aged 65 or older. As the most common ...